Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G6-31
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Pulmonary (aerosol)
01
Overview
G6-31 is a mouse monoclonal antibody (mAb) that targets vascular endothelial growth factor A (VEGF-A). It is used to inhibit the growth of tumors by blocking the VEGF-A/VEGFR2 pathway, which is crucial for angiogenesis, the formation of new blood vessels. G6-31 has been studied in various models, including K-ras mutated adenocarcinoma in mice, where it showed efficacy in reducing tumor burden when administered both systemically and via aerosol[1][2]. It is a high-affinity antibody with potential applications in treating cancers by inhibiting angiogenesis[1][2].
- Other names
- Mouse Anti-VEGFA Recombinant Antibody (clone mAb G6-31)
02
Targets
Beyond the preview
Go deeper on G6-31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G6-31.